Effectiveness of MR-guided LITT Therapy in Irresectable Glioblastoma (EMITT)
EMITT
(Cost)Effectiveness of MR-guided LITT Therapy in Patients With Primary Irresectable Glioblastoma: a Prospective Multicenter Randomized Controlled Trial (EMITT)
1 other identifier
interventional
238
1 country
7
Brief Summary
The aim of this study is to investigate the (cost-)effectiveness of LITT (Laser Interstitial Thermal Therapy) in primary irresectable glioblastoma. Glioblastoma are the most common malignant brain tumors and are, due to their devastating nature and the fact that these tumors occur at a relatively young age (median 59 years), responsible for up to 7% of total life years lost from cancer before the age of 70. The current treatment of glioblastoma consists of maximal safe surgery combined with adjuvant chemoradiation therapy (CRT). However, despite this aggressive treatment, these patients still face a poor prognosis (median overall survival 14.5 - 18.5 months). In addition to that, around 30% of the patients diagnosed with a glioblastoma are not suitable for surgery. These patients miss the benefit of a resection and face an even worse prognosis (median overall survival 5.1 months). The primary aim of this project is to investigate whether laser therapy combined with CRT improves overall survival, without compromising quality of life, in comparison with CRT alone in patients with primary irresectable glioblastoma.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for phase_3
Started Apr 2022
Longer than P75 for phase_3
7 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
March 23, 2022
CompletedFirst Posted
Study publicly available on registry
April 8, 2022
CompletedStudy Start
First participant enrolled
April 8, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 31, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
October 31, 2027
ExpectedApril 10, 2024
September 1, 2023
3.6 years
March 23, 2022
April 9, 2024
Conditions
Outcome Measures
Primary Outcomes (2)
Overall survival
Percentage of patients still alive for a given period of time after randomization.
Depending on which event occurs first: either when a study participant dies or at the end of the trial (61 months).
Health Related Quality of Life (HR-QoL)
QoL measured with the QLQ-C30BN20 at 5 months after randomization.
At 5 months after randomization
Secondary Outcomes (10)
Costs
At 1, 2, 3, 4, 5, 6, 12, 18, 30, 42 and 54 months after randomization.
Ablation rate
Using the MRI made right after LITT procedure
Progression Free Survival (PFS)
During the entire study period, estimated 18 months for each patient
Disease Specific Survival (DSS)
During the entire study period, estimated 18 months for each patient
Complication rate
During the entire study period, estimated 18 months for each patient
- +5 more secondary outcomes
Study Arms (2)
Control group (biopsy group)
OTHERStandard of care: biopsy + adjuvant treatment
Intervention group (LITT group)
EXPERIMENTALBiopsy + LITT + adjuvant treatment
Interventions
LITT is a minimally invasive neurosurgical procedure in which a laser catheter is placed into the tumor and warms the tumor to such an extent that tumor tissue is destroyed. LITT is performed under MR-guidance.
A sample of tissue from the tumor is obtained to confirm the diagnosis.
Eligibility Criteria
You may qualify if:
- Informed consent, age \>18 years
- Suspected glioblastoma
- Supratentorial localization
- Patient is not amendable for surgical resection as decided by the tumor board
- Safe trajectory/trajectories possible for ablation of at least 70% of the tumor, avoiding eloquent structures
- Karnofsky Performance Status (KPS) \>=70
You may not qualify if:
- Contra-indication for general anesthesia or MRI
- Non-glioblastoma diagnosis on pathology analysis
- No final pathology available
- Pregnancy
- Insufficient command of the Dutch language by the patient or a family member, making it impossible to fill in the questionnaires
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Radboud University Medical Centerlead
- Dutch National Health Care Institutecollaborator
- ZonMw: The Netherlands Organisation for Health Research and Developmentcollaborator
- UMC Utrechtcollaborator
Study Sites (7)
Amsterdam Medical Center
Amsterdam, Netherlands
University Medical Center Groningen
Groningen, Netherlands
Maastricht University Medical Center
Maastricht, Netherlands
Radboud University Medical Center
Nijmegen, Netherlands
Erasmus Medical Center
Rotterdam, Netherlands
Elisabeth Tweesteden Ziekenhuis
Tilburg, Netherlands
University Medical Center Utrecht
Utrecht, Netherlands
Related Publications (37)
Incidentie Hersentumoren. IKNL. https://www.iknl.nl/kankersoorten/hersentumoren/registratie/incidentie. Accessed October 7, 2020.
BACKGROUNDSiegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015 Jan-Feb;65(1):5-29. doi: 10.3322/caac.21254. Epub 2015 Jan 5.
PMID: 25559415BACKGROUNDRouse C, Gittleman H, Ostrom QT, Kruchko C, Barnholtz-Sloan JS. Years of potential life lost for brain and CNS tumors relative to other cancers in adults in the United States, 2010. Neuro Oncol. 2016 Jan;18(1):70-7. doi: 10.1093/neuonc/nov249. Epub 2015 Oct 12.
PMID: 26459813BACKGROUNDStupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005 Mar 10;352(10):987-96. doi: 10.1056/NEJMoa043330.
PMID: 15758009BACKGROUNDWeller M, van den Bent M, Hopkins K, Tonn JC, Stupp R, Falini A, Cohen-Jonathan-Moyal E, Frappaz D, Henriksson R, Balana C, Chinot O, Ram Z, Reifenberger G, Soffietti R, Wick W; European Association for Neuro-Oncology (EANO) Task Force on Malignant Glioma. EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. Lancet Oncol. 2014 Aug;15(9):e395-403. doi: 10.1016/S1470-2045(14)70011-7.
PMID: 25079102BACKGROUNDBrown TJ, Brennan MC, Li M, Church EW, Brandmeir NJ, Rakszawski KL, Patel AS, Rizk EB, Suki D, Sawaya R, Glantz M. Association of the Extent of Resection With Survival in Glioblastoma: A Systematic Review and Meta-analysis. JAMA Oncol. 2016 Nov 1;2(11):1460-1469. doi: 10.1001/jamaoncol.2016.1373.
PMID: 27310651BACKGROUNDDe Witt Hamer PC, Ho VKY, Zwinderman AH, Ackermans L, Ardon H, Boomstra S, Bouwknegt W, van den Brink WA, Dirven CM, van der Gaag NA, van der Veer O, Idema AJS, Kloet A, Koopmans J, Ter Laan M, Verstegen MJT, Wagemakers M, Robe PAJT; Quality Registry Neuro Surgery glioblastoma working group from the Dutch Society of Neurosurgery. Between-hospital variation in mortality and survival after glioblastoma surgery in the Dutch Quality Registry for Neuro Surgery. J Neurooncol. 2019 Sep;144(2):313-323. doi: 10.1007/s11060-019-03229-5. Epub 2019 Jun 24.
PMID: 31236819BACKGROUNDHaj A, Doenitz C, Schebesch KM, Ehrensberger D, Hau P, Putnik K, Riemenschneider MJ, Wendl C, Gerken M, Pukrop T, Brawanski A, Proescholdt MA. Extent of Resection in Newly Diagnosed Glioblastoma: Impact of a Specialized Neuro-Oncology Care Center. Brain Sci. 2017 Dec 25;8(1):5. doi: 10.3390/brainsci8010005.
PMID: 29295569BACKGROUNDAshraf O, Patel NV, Hanft S, Danish SF. Laser-Induced Thermal Therapy in Neuro-Oncology: A Review. World Neurosurg. 2018 Apr;112:166-177. doi: 10.1016/j.wneu.2018.01.123. Epub 2018 Feb 2.
PMID: 29410102BACKGROUNDViozzi I, Guberinic A, Overduin CG, Rovers MM, Ter Laan M. Laser Interstitial Thermal Therapy in Patients with Newly Diagnosed Glioblastoma: A Systematic Review. J Clin Med. 2021 Jan 19;10(2):355. doi: 10.3390/jcm10020355.
PMID: 33477796BACKGROUNDWilliams D, Loshak H. Laser Interstitial Thermal Therapy for Epilepsy and/or Brain Tumours: A Review of Clinical Effectiveness and Cost-Effectiveness [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 Jun 17. Available from http://www.ncbi.nlm.nih.gov/books/NBK545597/
PMID: 31449372BACKGROUNDWeller M, van den Bent M, Preusser M, Le Rhun E, Tonn JC, Minniti G, Bendszus M, Balana C, Chinot O, Dirven L, French P, Hegi ME, Jakola AS, Platten M, Roth P, Ruda R, Short S, Smits M, Taphoorn MJB, von Deimling A, Westphal M, Soffietti R, Reifenberger G, Wick W. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol. 2021 Mar;18(3):170-186. doi: 10.1038/s41571-020-00447-z. Epub 2020 Dec 8.
PMID: 33293629BACKGROUNDMaringwa J, Quinten C, King M, Ringash J, Osoba D, Coens C, Martinelli F, Reeve BB, Gotay C, Greimel E, Flechtner H, Cleeland CS, Schmucker-Von Koch J, Weis J, Van Den Bent MJ, Stupp R, Taphoorn MJ, Bottomley A; EORTC PROBE Project and Brain Cancer Group. Minimal clinically meaningful differences for the EORTC QLQ-C30 and EORTC QLQ-BN20 scales in brain cancer patients. Ann Oncol. 2011 Sep;22(9):2107-2112. doi: 10.1093/annonc/mdq726. Epub 2011 Feb 15.
PMID: 21324954BACKGROUNDTaphoorn MJ, Stupp R, Coens C, Osoba D, Kortmann R, van den Bent MJ, Mason W, Mirimanoff RO, Baumert BG, Eisenhauer E, Forsyth P, Bottomley A; European Organisation for Research and Treatment of Cancer Brain Tumour Group; EORTC Radiotherapy Group; National Cancer Institute of Canada Clinical Trials Group. Health-related quality of life in patients with glioblastoma: a randomised controlled trial. Lancet Oncol. 2005 Dec;6(12):937-44. doi: 10.1016/S1470-2045(05)70432-0.
PMID: 16321761BACKGROUNDGarside R, Pitt M, Anderson R, Rogers G, Dyer M, Mealing S, Somerville M, Price A, Stein K. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation. Health Technol Assess. 2007 Nov;11(45):iii-iv, ix-221. doi: 10.3310/hta11450.
PMID: 17999840BACKGROUNDMedvid R, Ruiz A, Komotar RJ, Jagid JR, Ivan ME, Quencer RM, Desai MB. Current Applications of MRI-Guided Laser Interstitial Thermal Therapy in the Treatment of Brain Neoplasms and Epilepsy: A Radiologic and Neurosurgical Overview. AJNR Am J Neuroradiol. 2015 Nov;36(11):1998-2006. doi: 10.3174/ajnr.A4362. Epub 2015 Jun 25.
PMID: 26113069BACKGROUNDMcDannold NJ, Jolesz FA. Magnetic resonance image-guided thermal ablations. Top Magn Reson Imaging. 2000 Jun;11(3):191-202. doi: 10.1097/00002142-200006000-00005.
PMID: 11145211BACKGROUNDLeuthardt EC, Duan C, Kim MJ, Campian JL, Kim AH, Miller-Thomas MM, Shimony JS, Tran DD. Hyperthermic Laser Ablation of Recurrent Glioblastoma Leads to Temporary Disruption of the Peritumoral Blood Brain Barrier. PLoS One. 2016 Feb 24;11(2):e0148613. doi: 10.1371/journal.pone.0148613. eCollection 2016.
PMID: 26910903BACKGROUNDMohammadi AM, Hawasli AH, Rodriguez A, Schroeder JL, Laxton AW, Elson P, Tatter SB, Barnett GH, Leuthardt EC. The role of laser interstitial thermal therapy in enhancing progression-free survival of difficult-to-access high-grade gliomas: a multicenter study. Cancer Med. 2014 Aug;3(4):971-9. doi: 10.1002/cam4.266. Epub 2014 May 9.
PMID: 24810945BACKGROUNDAhluwalia M, Barnett GH, Deng D, Tatter SB, Laxton AW, Mohammadi AM, Leuthardt E, Chamoun R, Judy K, Asher A, Essig M, Dietrich J, Chiang VL. Laser ablation after stereotactic radiosurgery: a multicenter prospective study in patients with metastatic brain tumors and radiation necrosis. J Neurosurg. 2019 Mar 1;130(3):804-811. doi: 10.3171/2017.11.JNS171273. Epub 2018 May 4.
PMID: 29726782BACKGROUNDRennert RC, Khan U, Bartek J, Tatter SB, Field M, Toyota B, Fecci PE, Judy K, Mohammadi AM, Landazuri P, Sloan AE, Kim AH, Leuthardt EC, Chen CC. Laser Ablation of Abnormal Neurological Tissue Using Robotic Neuroblate System (LAANTERN): Procedural Safety and Hospitalization. Neurosurgery. 2020 Apr 1;86(4):538-547. doi: 10.1093/neuros/nyz141.
PMID: 31076762BACKGROUNDCabantog AM, Bernstein M. Complications of first craniotomy for intra-axial brain tumour. Can J Neurol Sci. 1994 Aug;21(3):213-8. doi: 10.1017/s0317167100041184.
PMID: 8000976BACKGROUNDPatel P, Patel NV, Danish SF. Intracranial MR-guided laser-induced thermal therapy: single-center experience with the Visualase thermal therapy system. J Neurosurg. 2016 Oct;125(4):853-860. doi: 10.3171/2015.7.JNS15244. Epub 2016 Jan 1.
PMID: 26722845BACKGROUNDHawasli AH, Bagade S, Shimony JS, Miller-Thomas M, Leuthardt EC. Magnetic resonance imaging-guided focused laser interstitial thermal therapy for intracranial lesions: single-institution series. Neurosurgery. 2013 Dec;73(6):1007-17. doi: 10.1227/NEU.0000000000000144.
PMID: 24056317BACKGROUNDStef van Buuren KG-O. mice: Multivariate Imputation by Chained Equations in R. Journal of Statistical Software 2011; Volume 45(issue 3)
BACKGROUNDS vB. Flexible imputation of missing data, second edition: Boca Raton; 2008.
BACKGROUNDCarreras G, Miccinesi G, Wilcock A, Preston N, Nieboer D, Deliens L, Groenvold M, Lunder U, van der Heide A, Baccini M; ACTION consortium. Missing not at random in end of life care studies: multiple imputation and sensitivity analysis on data from the ACTION study. BMC Med Res Methodol. 2021 Jan 9;21(1):13. doi: 10.1186/s12874-020-01180-y.
PMID: 33422019BACKGROUNDKamath AA, Friedman DD, Hacker CD, Smyth MD, Limbrick DD Jr, Kim AH, Hawasli AH, Leuthardt EC. MRI-Guided Interstitial Laser Ablation for Intracranial Lesions: A Large Single-Institution Experience of 133 Cases. Stereotact Funct Neurosurg. 2017;95(6):417-428. doi: 10.1159/000485387. Epub 2018 Jan 17.
PMID: 29339639BACKGROUNDRiche M, Amelot A, Peyre M, Capelle L, Carpentier A, Mathon B. Complications after frame-based stereotactic brain biopsy: a systematic review. Neurosurg Rev. 2021 Feb;44(1):301-307. doi: 10.1007/s10143-019-01234-w. Epub 2020 Jan 4.
PMID: 31900737BACKGROUNDJackson C, Westphal M, Quinones-Hinojosa A. Complications of glioma surgery. Handb Clin Neurol. 2016;134:201-18. doi: 10.1016/B978-0-12-802997-8.00012-8.
PMID: 26948356BACKGROUNDRahmathulla G, Recinos PF, Kamian K, Mohammadi AM, Ahluwalia MS, Barnett GH. MRI-guided laser interstitial thermal therapy in neuro-oncology: a review of its current clinical applications. Oncology. 2014;87(2):67-82. doi: 10.1159/000362817. Epub 2014 Jul 3.
PMID: 24994550BACKGROUNDFranck P, Henderson PW, Rothaus KO. Basics of Lasers: History, Physics, and Clinical Applications. Clin Plast Surg. 2016 Jul;43(3):505-13. doi: 10.1016/j.cps.2016.03.007.
PMID: 27363764BACKGROUNDDi L, Wang CP, Shah AH, Eichberg DG, Semonche AM, Sanjurjo AD, Luther EM, Jermakowicz WJ, Komotar RJ, Ivan ME. A Cohort Study on Prognostic Factors for Laser Interstitial Thermal Therapy Success in Newly Diagnosed Glioblastoma. Neurosurgery. 2021 Aug 16;89(3):496-503. doi: 10.1093/neuros/nyab193.
PMID: 34156076BACKGROUNDPatel NV, Jethwa PR, Shetty A, Danish SF. Does the real-time thermal damage estimate allow for estimation of tumor control after MRI-guided laser-induced thermal therapy? Initial experience with recurrent intracranial ependymomas. J Neurosurg Pediatr. 2015 Apr;15(4):363-71. doi: 10.3171/2014.10.PEDS13698. Epub 2015 Jan 16.
PMID: 25580512BACKGROUNDNakagawa M, Matsumoto K, Higashi H, Furuta T, Ohmoto T. Acute effects of interstitial hyperthermia on normal monkey brain--magnetic resonance imaging appearance and effects on blood-brain barrier. Neurol Med Chir (Tokyo). 1994 Oct;34(10):668-75. doi: 10.2176/nmc.34.668.
PMID: 7529367BACKGROUNDRieke V, Butts Pauly K. MR thermometry. J Magn Reson Imaging. 2008 Feb;27(2):376-90. doi: 10.1002/jmri.21265.
PMID: 18219673BACKGROUNDNeutel CLG, Viozzi I, Overduin CG, Rijpma A, Grutters JPC, Hannink G, van Eijsden P, Robe PA, Rovers MM, Ter Laan M. Study protocol for a multicenter randomised controlled trial on the (cost)effectiveness of biopsy combined with same-session MR-guided LITT versus biopsy alone in patients with primary irresectable glioblastoma (EMITT trial). BMC Cancer. 2023 Aug 23;23(1):788. doi: 10.1186/s12885-023-11282-7.
PMID: 37612610DERIVED
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Mark ter Laan, MD, PhD
Radboud University Medical Center
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
March 23, 2022
First Posted
April 8, 2022
Study Start
April 8, 2022
Primary Completion
October 31, 2025
Study Completion (Estimated)
October 31, 2027
Last Updated
April 10, 2024
Record last verified: 2023-09
Data Sharing
- IPD Sharing
- Will share
Data will be shared with other researchers. All data will be made findable and shared for reuse and/or verification. Restrictions on data sharing only apply to MRI images due to privacy. Metadata will be published in a data repository (Radboud Data Repository). This way the data is findable. When desired, external researchers can request our data.